OR-GUROBI-OPTIMIZATION
18.8.2020 15:02:14 CEST | Business Wire | Press release
Gurobi Optimization, LLC and River Logic, Inc today announced that River Logic has chosen the Gurobi Optimizer as the preferred mathematical optimization solver for its prescriptive analytics platform. By embedding the Gurobi Optimizer in its platform, River Logic expects its customers to take full advantage of the capabilities of this best-of-breed solver, leading in many cases to faster solve times and increased profit opportunities.
After a thorough evaluation and selection process, River Logic – which had been using another commercial solver as a component of its prescriptive analytics platform for many years – decided to switch to the Gurobi Optimizer.
River Logic’s Chief Technology Officer Peter Bull said: "We are tremendously excited to announce a long-term partnership with Gurobi to harness the power of their optimization solver technology with River Logic’s unique prescriptive analytics cloud SaaS application. River Logic, now together with Gurobi, is at the forefront of driving prescriptive analytics solutions across an increasing number of industries and organizations, helping them to transform their business operations and capabilities."
There were three main reasons behind River Logic’s decision to switch to the Gurobi Optimizer:
- Performance : The Gurobi Optimizer is the world’s fastest and most powerful mathematical optimization solver, which is constantly setting new industry standards in terms of speed and solution quality. With the Gurobi Optimizer as a key component of River Logic’s solutions, River Logic customers – many of whom are business users without a background in mathematical programming – will see a substantial reduction in the time it takes to optimally solve complex business problems.
- Vision : Gurobi’s R&D team – which is comprised of the leading experts in the mathematical optimization software industry – is fully focused on developing and delivering the best mathematical optimization solver technology. This goes hand-in-hand with River Logic’s commitment to providing the best planning and decision-support solutions to its global customers. With Gurobi and River Logic’s commitment to continuous improvement and cutting-edge innovation, River Logic customers can be assured that they are using the state-of-the-art solver – today and in the future.
- Support : Gurobi’s Support team – which is made up of PhD-level mathematical optimization specialists – is dedicated to providing world-class support for customers using the Gurobi Optimizer. River Logic’s technical team and customers will have access to Gurobi’s Support team – who will be there to assist them and make sure they are able to utilize mathematical optimization as effectively as possible in River Logic’s platform.
Gurobi’s Chief Revenue Officer Duke Perrucci commented: “We are thrilled to have the Gurobi Optimizer power River Logic's suite of first-class optimization applications. Our relentless focus on innovation will allow River Logic's customers to tackle the world's most complex problems at speed and with confidence.”
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability.
As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit www.gurobi.com or call +1 713 871 9341.
About River Logic
River Logic is on a mission to ensure companies across the globe drive maximum value with every decision, no matter how complex the business problem or how quickly markets shift. As a global innovator in advanced analytics, River Logic offers optimization solutions purpose-built for business users rather than data scientists. Its cloud-based solutions enable enterprise-wide optimization through a revolutionary cloud experience that offers rapid scenario collaboration, data management, workflows, scalability, and more. Companies are finally able to align decisions around complex trade-offs with overarching business objectives without sacrificing speed, agility, and flexibility. For more information, please visit www.riverlogic.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005265/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
